Zentalis制药公司宣布,其Denali临床试验的2a阶段患者入组工作已全部完成。该阶段旨在评估候选药物在特定患者群体中的安全性与初步疗效。公司计划于2026年上半年获得关键剂量确认数据,这将为后续临床开发提供重要依据。
此次进展标志着Zentalis在肿瘤治疗领域迈出关键一步。若剂量确认结果积极,公司将加速推进后续研究,有望为患者提供新的治疗选择。行业观察人士正密切关注该项目的后续数据披露。
Zentalis制药公司宣布,其Denali临床试验的2a阶段患者入组工作已全部完成。该阶段旨在评估候选药物在特定患者群体中的安全性与初步疗效。公司计划于2026年上半年获得关键剂量确认数据,这将为后续临床开发提供重要依据。
此次进展标志着Zentalis在肿瘤治疗领域迈出关键一步。若剂量确认结果积极,公司将加速推进后续研究,有望为患者提供新的治疗选择。行业观察人士正密切关注该项目的后续数据披露。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.